Design and development of efficient synthetic strategies for the chiral synthesis of novel ketolide antibiotic, nafithromycin (WCK 4873)

[1]  S. Pawar,et al.  WCK 4873 (INN: Nafithromycin): Structure-Activity relationship (SAR) identifying a novel lactone ketolide with activity against Streptococcus pneumoniae (SPN) and Streptococcus pyogenes (SPY) , 2022, Results in Chemistry.

[2]  V. Rane,et al.  Enantiomeric Separation of (R)-5-(1-Hydroxyethyl)-2-(pyridine- 2-yl)-[1, 3, 4]-thiadiazole, an Intermediate of Nafithromycin on Immobilized Amylose Based Stationary Phase , 2022, Analytical Chemistry Letters.

[3]  K. Patil,et al.  Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  S. K. Sartori,et al.  Use of chiral auxiliaries in the asymmetric synthesis of biologically active compounds: A review. , 2019, Chirality.

[5]  K. Patil,et al.  Enantiomeric Separation and Thermodynamic investigation of (R)-5-[1-(4-Nitrobenzylsulfonyloxy)-ethyl]-5-(pyridine-2-yl)- [1,3,4]-thiadiazole, a Key Intermediate of Nafithromycin , 2019, Analytical Chemistry Letters.

[6]  K. Patil,et al.  Identification and Quantification of Related Impurities of a Novel Ketolide Antibiotic Nafithromycin , 2019, Chromatographia.

[7]  G. Dinos.  The macrolide antibiotic renaissance , 2017, British journal of pharmacology.

[8]  T. Grossman,et al.  Resistance to Macrolide Antibiotics in Public Health Pathogens. , 2016, Cold Spring Harbor perspectives in medicine.

[9]  Dubravko Jelić,et al.  From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials , 2016, Antibiotics.

[10]  I. Agranat,et al.  The predicated demise of racemic new molecular entities is an exaggeration , 2012, Nature Reviews Drug Discovery.

[11]  S. Douthwaite,et al.  The Ketolides , 2012, Drugs.

[12]  Silas W Smith.  Chiral toxicology: it's the same thing...only different. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  William M. Lee,et al.  Telithromycin‐associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases , 2009, Hepatology.

[14]  Jinhua J. Song,et al.  Asymmetric synthesis of active pharmaceutical ingredients. , 2006, Chemical reviews.

[15]  D. Low,et al.  Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  A. Bryskier.  Ketolides-telithromycin, an example of a new class of antibacterial agents. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  R. Wise,et al.  The in vitro activity of ABT773, a new ketolide antimicrobial agent. , 2000, The Journal of antimicrobial chemotherapy.

[18]  A. Bryskier,et al.  Novelties in the field of anti-infective compounds in 1999. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  C. Fogarty,et al.  The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. , 1998, The Journal of antimicrobial chemotherapy.

[20]  W. A. Nugent,et al.  Beyond Nature's Chiral Pool: Enantioselective Catalysis in Industry , 1993, Science.

[21]  P. Wiley,et al.  Erythromycin. I. Properties and Degradation Studies1 , 1954 .